We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Direct Reprogramming of Fibroblasts into Melanocytes Avoids Cancer Threat

By LabMedica International staff writers
Posted on 29 Dec 2014
A team of cell biologists has successfully induced fibroblasts to convert to functional melanocytes (melanin-producing skin cells) without going through a preliminary pluripotent stage.

Direct reprogramming provides a fundamentally new approach for the manufacture of patient-specific cells that greatly reduces the danger of inadvertently generating tumors. More...
In the current study, investigators at the University of Pennsylvania (Philadelphia, USA) and their colleagues devised a method for directly reprogramming fibroblasts into functional melanocytes.

The first step was to identify 10 specific cell transcription factors linked to melanocyte development. Transcription factor screening assays revealed that three transcription factors - SOX10 (sex determining region Y-box 10), MITF (microphthalmia-associated transcription factor), and PAX3 (paired box 3) - out of those 10 were sufficient to induce fibroblasts to transform into melanocytes.

Results published in the December 16, 2014, online edition of the journal Nature Communications revealed that induced melanocytes (iMels) produced by this technique activated melanocyte-specific networks, expressed components of the pigment production and delivery system, and produced melanosomes. Human iMels properly integrated into the dermal-epidermal junction and produced and delivered melanin pigment to surrounding keratinocytes in a three-dimensional organotypic skin reconstruct. Furthermore, human iMels generated pigmented epidermis and hair follicles in skin reconstitution assays in vivo.

"We did a huge amount of work," said senior author Dr. Xiaowei Xu, associate professor of pathology and laboratory medicine at the University of Pennsylvania. "We eliminated all the combinations of the other transcription factors and found that these three are essential. Through direct reprogramming, we do not have to go through the pluripotent stem cell stage, but directly convert fibroblasts to melanocytes. So these cells do not have tumorigenicity. By generating melanocytes from the fibroblasts of melanoma patients, we can screen not only to find why these patients easily develop melanoma, but possibly use their cells to screen for small compounds that can prevent melanoma from happening."

Related Links:
University of Pennsylvania


New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.